Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
A Texas GOP congressman is retiring. Trump just endorsed his identical twin to replace him. - 2Why the chemtrail conspiracy theory lingers and grows – and why Tucker Carlson is talking about it
- 3Holiday season sees uptick in norovirus cases, according to CDC
- 4This Week In Space podcast: Episode 186 — Snow on the Moon?
- 5Zelensky sees win for Ukraine as EU finally reaches funding deal
- RFK Jr.’s vaccine advisers plan biggest change yet to childhood schedule
- Trump says Venezuela will start 'turning over' oil to the U.S. Is that the reason he toppled Maduro — or is it something else?
- FDA proposes use of sunscreen ingredient popular in other countries
- Medtronic has 'significant firepower' for multiple acquisitions, executives say
- NASA just launched Artemis 2. What happens today could make or break the moon mission
- Reports: Germany plans expansion of foreign intelligence powers
- Before Cheap Cars Were Common, This Fiat Changed Everyday Life for Millions
- Australia PM tries to reassure public as panic buying sees fuel demand surge 400% in some regions
- Kobe Bryant called this WNBA star the 'Gold Mamba.' She turned his advice to her into a tattoo.
